Table 4.
Immunotherapy in soft tissue sarcomas
| Study | Population | Study phase, status | Drug and schedule | Patients | Overall response rate (%) |
|---|---|---|---|---|---|
| Mackall et al., 2016 [88] | Synovial sarcoma | I/II, recruiting | NY-ESO-1c259 SPEAR T-cells Cohort 1 and 2: FL 30 mg/m2/day, day 1–4; CTX 1800 mg/m2/day day 1–2 Cohort 3: CTX 1800 mg/m2/day day 1–2 Cohort 4: FL 30 mg/m2/day, day 1–3; CTX 600 mg/m2/day; day 1–3 |
Cohort 1: 15 Cohort 2: 2 Cohort 3: 2 Cohort 4: 0 |
Cohort 1: 50 Cohort 2: NA Cohort 3: NA Cohort 4: NA |
| Italiano et al., 2016 [90] | LMS (Arm A), UPS (Arm B), GIST (Arm C), OS (Arm D), other sarcomas (Arm E) | II, recruiting in arm B and D | Pembrolizumab 200 mg i.v. 3-weekly; CTX 50 mg BID 1week on, 1 week off | Arm A: 15 Arm B: 0 Arm C: 10 Arm D: 0 Arm E: 16 |
No objective responses |
| Burgess et al., 2016 [89] | All-type STS (arm A) and BS (arm B) | II, completed | Pembrolizumab, 200mg i.v., 3-weekly | Arm A: 40 Arm B: 40 |
Arm A: 17.5 (UPS, LPS, SS) Arm B: 5 (OS, CS) |
| Paoluzzi et al., 2016 [91] | All-type STS and BS | Retrospective | Arm A: nivolumab 3 mg/kg i.v., 2-weekly Arm B: nivolumab 3 mg/kg i.v., 2-weekly + pazopanib 800 mg/day |
Arm A: 10 Arm B: 18 |
Arm A: 10 (CS) Arm B: 11 (ES, OS) |
| George et al., 2016 [90] | Leiomyosarcoma | II | Nivolumab 3 mg/kg i.v., 2-weekly | 12 | No objective responses |
BS bone sarcomas; CS chondrosarcoma; CTX cyclophosphamide; ES epithelioid sarcoma; FL fludarabine; GIST Gastrointestinal stromal tumors; LMS leiomyosarcoma; LPS liposarcoma; NA not available; OS osteosarcoma; SS synovial sarcoma; STS soft tissue sarcomas; UPS undifferentiated pleomorphic sarcoma